Drug Trial Radar · NCT01153672
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Nov 2010
Primary completion
Jul 2012
Study completion Aug 11, 2016
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 30, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work better by making tumor cells more sensitive to the drug
Conditions
- Male Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
Interventions
vorinostatDrug
Given PO
laboratory biomarker analysisOther
Correlative studies
biopsyProcedure
Optional correlative studies
F-18 16 alpha-fluoroestradiolRadiation
Correlative studies
positron emission tomographyProcedure
Correlative studies
anastrozoleDrug
Given PO
letrozoleDrug
Given PO
exemestaneDrug
Given PO
gene expression analysisGenetic
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Clinical Benefit According to RECISTTime frame: Up to approximately 5 years
- Duration of ResponseTime frame: Up to approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.